drugset / Trial / NCT02476175

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder

NCT02476175

Phase 3 Completed 35 enrolled CHU de Quebec-Universite Laval
NaSingle-groupOpen-labelTreatment

Summary

The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.

Timeline

Start
2013-04
Primary completion
2016-04
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg
Subject Mirabegron Other / unclassified 50 mg

Indications